UCB’s $2B Bet on Rare Disease, BioNTech’s IPO Haircut, & Greenwood Eases Out the Door

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more.


You may also like

Merck’s Ebola Vaccine Triumph, Weill’s $106M Neurohub & Teva’s Reversal
Takeda’s Busy Week, Halozyme’s Stumble, and New FDA Commish On Deck
Amgen’s Bet on BeiGene, David Hung’s Megaround, & Zolgensma Speed Bump
Vertex’s Watershed for CF, Biogen’s Head-Scratcher, and Seattle Genetics Nails HER2Climb